In conclusion, we examined the effects of SFRPs on the prognosis of AD patients in this study and found that high levels of SFRP1 and SFRP2 may reduce the occurrence of end-point events and have a beneficial effect on prognosis, while high SFRP3 levels may increase adverse events and lead to a poor prognosis. The gene discussed is SFRP2; the disease is Alzheimer disease.